28 Feb
Latest News

Price negotiation article published – link MArS negotiation boot camp

Price negotiation strategy is most of the times also linked to the available evidence and the potential bet on future data. Gladwell et al. have just published a nice simulation approach with the example in the UK which can also be utilized in the D-A-CH context. For the German AMNOG that approach is also relevant for orphan drugs earlier in the process also with the G-BA and for any pharmaceutical within the price negotiations with the GKV-SV.

The article is available in Value in Health.

MArS has long-lasting experience in (price) negotiations in the D-A-CH regions. We have also developed an internal and successful negotiation boot camp utilizing virtual reality. Contact us for a live demonstration.

26 Feb
Publications

Secondary HE analysis on the EFFORT study published!

Existing guidelines support the importance of nutritional interventions for medical inpatients at malnutrition risk to alleviate the impact of malnutrition on outcomes. MArS in conjunction with the investigators of the EFFORT – a pragmatic, investigator-initiated, open-label, multicenter Swiss trial have developed and executed a probabilistic health economic analysis. Our evaluation demonstrates that in-hospital nutritional support for medical inpatients is a highly cost-effective intervention in Switzerland to reduce risks for ICU admissions and hospital-associated complications, while improving patient survival.

The full article is available on the website of the Journal of Clinical Nutrition

MArS has a strong background in health economics, the related data analytics, medical writing and communication with payers. We have developed various health economic analyses in the last years which lead to over 35 manuscripts in scientific journals and more than 150 presentations at conferences.

12 Feb
Latest News

MArS is now a proud member of the Head Association of Digital Health Care in Germany!!

The Head Association of Digital Health Care (SVDGV) has just been established in 2019 also driven by the new regulations on reimbursement for medical apps. MArS is a member and joined the working groups on reimbursement and evidence.

MArS has a vast majority of experience in the German reimbursement landscape, submissions and price negotiations and will be able to also transfer that into the new field for reimbursement of medical apps. Contact us.

05 Feb
Latest News

Country update Germany January 2020 – what’s new for market access?

MArS has created another country profile update for Germany as of January 2020 – a summary is available below – the full report is available on request.

As summary:

  • G-BA post-resolution comittments need now to follow the new IQWiG guide
  • Digital care Act: Milestones for the specifications of process documents by the BfArM and GKV-SV were made public. Applications for health apps are expected to be open in April 2020.
  • New draft law under discussion with respect to emergency care
  • Draft law also discussed with respect to an additional supervisory resources for selective contracts with respect to medical devices and new procedures including the set-up of an arbitration board

MArS has vast experience in submissions, pricing and negotiations in Germany for pharmaceuticals, medical devices and diagnostics.